Literature DB >> 23520055

Assessing whether there is a cancer premium for the value of a statistical life.

W Kip Viscusi1, Joel Huber, Jason Bell.   

Abstract

This article estimates whether there is a cancer risk premium for the value of a statistical life using stated preference valuations of cancer risks for a large, nationally representative US sample. The present value of an expected cancer case that occurs after a one decade latency period is $10.85m, consistent with a cancer premium that is 21% greater than the median value of a statistical life estimates for acute fatalities. This cancer premium is smaller than the premium proposed for policy analyses in the UK and the USA. There is also a greater premium for policies that reduce cancer risks to zero and for risk reductions affecting those who perceive themselves to have a greater than average probability of having cancer.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer; risk; stated preference; value of a statistical life (VSL)

Mesh:

Year:  2013        PMID: 23520055     DOI: 10.1002/hec.2919

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  10 in total

1.  Measuring the end-of-life premium in cancer using individual ex ante willingness to pay.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2017-08-12

2.  Pricing the global health risks of the COVID-19 pandemic.

Authors:  W Kip Viscusi
Journal:  J Risk Uncertain       Date:  2020-11-02

3.  Measuring the value of mortality risk reductions in Turkey.

Authors:  Cem Tekeşin; Shihomi Ara
Journal:  Int J Environ Res Public Health       Date:  2014-07-04       Impact factor: 3.390

Review 4.  Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics.

Authors:  Liz Morrell; Sarah Wordsworth; Sian Rees; Richard Barker
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

5.  Effect of Income Heterogeneity on Valuation of Mortality Risk in Taiwan: An Application of Unconditional Quantile Regression Method.

Authors:  Je-Liang Liou
Journal:  Int J Environ Res Public Health       Date:  2019-05-09       Impact factor: 3.390

6.  The forgotten numbers: A closer look at COVID-19 non-fatal valuations.

Authors:  Thomas J Kniesner; Ryan Sullivan
Journal:  J Risk Uncertain       Date:  2020-11-04

7.  The price of curing cancer.

Authors:  Afschin Gandjour
Journal:  BMC Health Serv Res       Date:  2021-12-11       Impact factor: 2.655

8.  Best-worst scaling survey of preferences regarding the adverse effects of tobacco use in China.

Authors:  Takeshi Mori; Takahiro Tsuge
Journal:  SSM Popul Health       Date:  2017-07-28

9.  Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks.

Authors:  Minah Park; Mark Jit; Joseph T Wu
Journal:  BMC Med       Date:  2018-09-05       Impact factor: 8.775

10.  Is prevention of suicide worth less? A comparison of the value per statistical life.

Authors:  Vimefall Elin; Persson Mattias; Olofsson Sara; Hultkrantz Lars
Journal:  Eur J Health Econ       Date:  2021-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.